Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) just unveiled an update.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Co., Ltd. have announced the results of the exercise of the right of dissenting shareholders in relation to their merger. During the designated declaration period, no dissenting shareholders exercised their rights, indicating a smooth progression towards the merger by absorption. This merger involves the exchange and cancellation of securities between the two companies, which are both incorporated in China. The merger is subject to Hong Kong disclosure requirements and may present challenges for U.S. shareholders in terms of rights enforcement due to jurisdictional differences.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceutical products, with a market presence primarily in China.
Average Trading Volume: 9,150,519
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.91B
For a thorough assessment of 1558 stock, go to TipRanks’ Stock Analysis page.